Meeting
2019 ASCO Annual Meeting
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
Authors
Haider Mahdi
The Cleveland Clinic, Cleveland, OH
Haider Mahdi , Steven Robert Schuster , David M. O'Malley , Donna M. McNamara , Reshma A. Rangwala , Shang-Ying Liang , Shweta Jain , Leonardo Nicacio , Hye Sook Chon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03657043
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5602)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5602
Abstract #
TPS5602
Poster Bd #
421a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2022 ASCO Annual Meeting
MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
First Author: Leslie M. Randall
Poster
2022 ASCO Annual Meeting
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
First Author: Lingying Wu
Poster
2014 ASCO Annual Meeting
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
First Author: Antonio Gonzalez-Martin